According to the report, the global iron deficiency anemia treatment market was valued at US$ 9.2 Bn in 2019 and is projected to expand at a CAGR of 8.7% from 2020 to 2030. Iron deficiency is the most common cause of anemia globally. Rise in prevalence of chronic kidney diseases, increase in risk of hemodilution in pregnant women, and surge in iron deficiency in individuals are the major factors anticipated to drive the global iron deficiency anemia treatment market during the forecast period. North America held a major share of the global iron deficiency anemia treatment market in 2019, due to large population suffering from iron deficiency, higher awareness about iron deficiency anemia, and increase in focus on new product launches by industry players. The iron deficiency anemia treatment market in Asia Pacific is expected to expand at a high CAGR of 9.5% from 2020 to 2030 due to increase in the number of geriatric patients suffering from iron deficiency and chronic kidney diseases.
Request Sample: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=81221
Rise in Prevalence of Iron Deficiency Anemia to Drive Market
Enquiry Before Buying: https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=81221
Ferrous Sulfate to Dominate Global Market
Request Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=81221
Tablets to be Preferred Dosage Form
In terms of dosage form, the global iron deficiency anemia treatment market has been categorized into tablets, capsules, and liquid. The tablets segment held major share of the global iron deficiency anemia treatment market in 2019. Tablet is the most stable, inexpensive, and widely available dosage form for the treatment of iron deficiency anemia. High acceptance of tablet dosage form in hospital inpatient and outpatient settings, rise in disposable income, and increase in government support are likely to drive the segment in the near future.
Hospital Pharmacies to Remain Major Distribution Channel
Based on distribution channel, the global iron deficiency anemia treatment market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market in 2019, owing to benefits such as individualized medication plan and quality medication and increase in the number of hospital pharmacies in developing countries.
Request for covid19 Impact Analysis: https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=81221
Growth Strategies of Key Players
Key players operating in the global iron deficiency anemia treatment market are AdvaCare Pharma, Akorn, Sun Pharmaceutical Industries Ltd., Akebia Therapeutics, Inc., Rockwell Medical, Inc., Vifor Pharma Management Ltd., Shield Therapeutics, AMAG Pharmaceuticals, and Pharmacosmos A/S. These companies engage in research & development to develop novel products in order to expand product offerings and customer base. In March 2020, Rockwell Medical, Inc. received the U.S. FDA approval for its intravenous formulation of Triferic, Triferic AVNU. This approval enabled the company to expand its product portfolio and strengthen its position in the global iron deficiency anemia treatment market.
Trending Reports:
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: https://www.transparencymarketresearch.com/
According to the report, the global iron deficiency anemia treatment market was valued at US$ 9.2 Bn in 2019 and is projected to expand at a CAGR of ~9% from 2020 to 2030.
Iron deficiency anemia is a common type of nutritional anemia and considered a major public health problem globally.
It results in low level of hemoglobin in the blood.
Moreover, a study conducted for national primary care database in Germany, Belgium, Spain, and Italy, states that the annual incidence rate of iron deficiency anemia ranged from 7.2 to 13.9 per 1,000 person-years.Ferrous Sulfate to Dominate Global MarketIn terms of drug type, the global iron deficiency anemia treatment market has been classified into ferrous sulfate, ferrous gluconate, ferrous fumerate, ferric hydroxide, sodium ferric gluconate, iron carbohydrates, and others.
The availability in generic form, low cost, and higher preference in the treatment of iron deficiency anemia is anticipated to boost the ferrous sulfate segment.Request COVID Analysis on Iron Deficiency Anemia Treatment Market –https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=81221Tablets to be Preferred Dosage FormIn terms of dosage form, the global iron deficiency anemia treatment market has been categorized into tablets, capsules, and liquid.
Tablet is the most stable, inexpensive, and widely available dosage form for the treatment of iron deficiency anemia.
